Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 11/20 | 0.48 |
| ▸ | BCHE | P06276 | 6/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927422 | 0.93 | CYP19A1 (0.44) | SLC6A2SLC6A4SLC6A3MAOBBCHE | |
| SCHEMBL6926244 | 0.91 | KDM4E (0.47) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL7505923 | 0.86 | ACHE (0.51) | BCHEACHEBACE1MEN1POLB | |
| SCHEMBL6921596 | 0.80 | HTR1A (0.43) | BCHE | |
| SCHEMBL6926720 | 0.79 | KDM4E (0.45) | MEN1POLBKMT2A | |
| SCHEMBL6924418 | 0.79 | HTR1B (0.51) | SLC6A4TP53 | |
| SCHEMBL6927871 | 0.78 | HTR6 (0.54) | BCHE | |
| SCHEMBL6920002 | 0.77 | HRH1 (0.53) | — | |
| SCHEMBL6921216 | 0.77 | HTR1B (0.53) | BCHEMEN1POLBKMT2A | |
| SCHEMBL6925519 | 0.76 | HTR6 (0.51) | BCHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514968-B1 | Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising | PHARMACIA & UPJOHN COMPANY | 2003-02-04 | — | — | US | claimed |
| EP-1210329-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001017963-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2001-03-15 | — | — | WO | claimed |
| US-6514968-B1 | Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising | PHARMACIA & UPJOHN COMPANY | 2003-02-04 | — | — | US | disclosed |
| EP-1210329-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001017963-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2001-03-15 | — | — | WO | disclosed |